肺癌是全球所有癌症中死亡率和发病率最高的一种。尽管有很多复杂的治疗选项，包括放疗、化疗、靶向药物治疗、免疫疗法以及这些治疗方法的组合，但在治疗抵抗、转移和晚期疾病的情况下，疗效较低，导致整体生存率较低。迫切需要发现早期诊断肺癌的新生物标志物和治疗靶点，以及确定药物治疗的疗效和结果。现在有大量的证据表明长链非编码RNA（lncRNA）具有诊断和预后价值。本综述简要讨论了lncRNA在肺癌治疗反应中的作用和机制的最新发现。版权所有 © 2023. Elsevier B.V. 发布。

Lung cancer has the highest mortality and morbidity rates among all cancers worldwide. Despite many complex treatment options, including radiotherapy, chemotherapy, targeted drugs, immunotherapy, and combinations of these treatments, efficacy is low in cases of resistance to therapy, metastasis, and advanced disease, contributing to low overall survival. There is a pressing need for the discovery of novel biomarkers and therapeutic targets for the early diagnosis of lung cancer and to determine the efficacy and outcomes of drug treatments. There is now substantial evidence for the diagnostic and prognostic value of long noncoding RNAs (lncRNAs). This review briefly discusses recent findings on the roles and mechanisms of action of lncRNAs in the responses to therapy in lung cancer.Copyright © 2023. Published by Elsevier B.V.